08:40 EDT Candel Therapeutics (CADL) files $300M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics reports Q2 EPS (9c) vs. (74c) last year
- Candel Therapeutics sees cash runway into 1Q27
- Candel Therapeutics receives EMA Orphan Designation for CAN-2409
- Candel Therapeutics: Promising Phase 3 Data and Strong Financial Runway Justify Buy Rating
- Candel Therapeutics initiated with a Buy at Brookline